[3-(1H-吡咯-1-基)苯基]甲醇 | 83140-94-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: [3-(1H-吡咯-1-基)苯基]甲醇
• 英文名称: (3-(1H-pyrrol-1-yl)phenyl)methanol
• 英文别名: 3-pyrrol-1-ylbenzyl alcohol；3-(1H-pyrrol-1-yl)phenylmethanol；3-(pyrrol-1-yl)phenylmethanol；3-(1-pyrrolyl)benzyl alcohol；[3-(1H-Pyrrol-1-yl)phenyl]methanol；(3-pyrrol-1-ylphenyl)methanol
• CAS: 83140-94-7
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: QQXDXYAGEXWXQU-UHFFFAOYSA-N

物化性质

• 熔点：
  70 °C
• 沸点：
  334.7±25.0 °C(Predicted)
• 密度：
  1.07±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2933990090
• 安全说明：
  S26,S36/37/39

SDS

Name:	[3-(1h-pyrrol-1-yl)phenyl]methanol 97% Material Safety Data Sheet
Synonym:
CAS:	83140-94-7

Section 1 - Chemical Product MSDS Name:[3-(1h-pyrrol-1-yl)phenyl]methanol 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
83140-94-7	[3-(1H-Pyrrol-1-yl)phenyl]methanol	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 83140-94-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: odorless
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 66 - 67 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H11NO
Molecular Weight: 173.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides, halogens, halogenated agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 83140-94-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
[3-(1H-Pyrrol-1-yl)phenyl]methanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 83140-94-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 83140-94-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 83140-94-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  [3-(1H-吡咯-1-基)苯基]甲醇 在 氢氧化钾 、 硫酸 、 三溴化磷 、 乙二醇 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 25.0h， 生成 methyl 3-pyrrol-1-ylphenylacetate
  参考文献：
  名称：

  吡咯-1-基苯甲酸和吡咯-1-基苯基乙酸的某些酰肼抑制铜依赖性胺氧化酶。

  摘要：

  制备了一些吡咯-1-基苯甲酸和吡咯-1-基苯乙酸的酰肼，并测试了它们对铜依赖性胺氧化酶（Cu-AOs）和FAD单胺氧化酶（MAOs）活性的影响。该化合物不是Cu-AO酶的底物，而是充当非竞争性抑制剂。吡咯-1-基苯基乙酸的酰肼对血浆胺氧化酶具有高度特异性（Ki = 0.5-1 microM）。相反，所有酰肼均是MAO活性的弱抑制剂。与酰肼衍生物一起孵育导致Cu-AOs的不可逆失活。因此，抑制意味着两个不同的步骤。第一个是酶抑制剂复合物的快速形成，并通过透析逆转。第二步，复合体不可逆转地转化，

  DOI：

  10.1021/jm00399a021
• 作为产物：
  描述：

  3-氨基苯甲酸甲酯 在 lithium aluminium tetrahydride 、 溶剂黄146 作用下， 以 乙醚 为溶剂， 反应 3.5h， 生成 [3-(1H-吡咯-1-基)苯基]甲醇
  参考文献：
  名称：

  吡咯-1-基苯甲酸和吡咯-1-基苯基乙酸的某些酰肼抑制铜依赖性胺氧化酶。

  摘要：

  制备了一些吡咯-1-基苯甲酸和吡咯-1-基苯乙酸的酰肼，并测试了它们对铜依赖性胺氧化酶（Cu-AOs）和FAD单胺氧化酶（MAOs）活性的影响。该化合物不是Cu-AO酶的底物，而是充当非竞争性抑制剂。吡咯-1-基苯基乙酸的酰肼对血浆胺氧化酶具有高度特异性（Ki = 0.5-1 microM）。相反，所有酰肼均是MAO活性的弱抑制剂。与酰肼衍生物一起孵育导致Cu-AOs的不可逆失活。因此，抑制意味着两个不同的步骤。第一个是酶抑制剂复合物的快速形成，并通过透析逆转。第二步，复合体不可逆转地转化，

  DOI：

  10.1021/jm00399a021

文献信息

• CARBOXYLIC ACID COMPOUND
  申请人：TODA Narihiro

  公开号：US20110053974A1

  公开（公告）日：2011-03-03

  To find a therapeutic agent and/or a preventive agent for diabetes mellitus or the like having excellent activity and safety. A compound represented by the following general formula (I), or a pharmacologically acceptable salt thereof. In the formula, X represents ═C(R5)- or ═N—; Y represents —O— or —NH—; L represents a bond or a substitutable C1-C3 alkylene group; M represents a substitutable C3-C10 cycloalkyl group, a substitutable C6-C10 aryl group, or a substitutable heterocyclic group; R 1 represents a C1-C6 alkyl group, a C3-C10 cycloalkyl group, a C1-C6 haloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 aliphatic acyl group, a C1-C6 alkoxy C1-C6 alkyl group, or a C6-C10 aryl group; and R 2 , R 3 , R 4 , and R 5 may be the same or different and each represent a hydrogen atom, a halogen atom, a C1-C3 alkyl group, a C1-C3 haloalkyl group, a C1-C3 alkoxy group, or a nitro group. In this connection, the alkyl group moieties of R 1 and R 2 may be bonded to each other to form a 5- to 6-membered heterocyclic ring containing one oxygen atom.

  寻找具有优异活性和安全性的治疗剂和/或预防剂，用于糖尿病或类似疾病。以下通用式（I）所代表的化合物，或其药理学上可接受的盐。在该式中，X代表 ═C(R5)- 或 ═N—；Y代表 —O— 或 —NH—；L代表键或可替代的C1-C3烷基链；M代表可替代的C3-C10环烷基，可替代的C6-C10芳基，或可替代的杂环基；R1代表C1-C6烷基，C3-C10环烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6脂肪酰基，C1-C6烷氧基C1-C6烷基，或C6-C10芳基；而R2、R3、R4和R5可以相同也可以不同，每个代表氢原子，卤原子，C1-C3烷基，C1-C3卤代烷基，C1-C3烷氧基，或硝基。在这种情况下，R1和R2的烷基基团可以结合在一起形成含有一个氧原子的5-至6-成员杂环环。
• 3-(Pyrrol-1-yl)phenylmethyl esters and intermediates
  申请人：FMC Corporation

  公开号：US04339457A1

  公开（公告）日：1982-07-13

  3-(Pyrrol-1-yl)phenylmethyl esters and intermediates having the general formula ##STR1## the use of the esters as pesticides, compositions thereof and a process for preparation are disclosed and exemplified.

  3-(吡咯-1-基)苯甲酸酯和具有通用公式##STR1##的中间体，揭示和举例了酯类化合物作为杀虫剂的用途，以及其组合物和制备方法。
• 一类新型含氮杂环衍生物、其制备方法及其作为药物的用途
  申请人：中国药科大学

  公开号：CN105566263A

  公开（公告）日：2016-05-11

  本发明涉及一种通式(I)所示的新型含氮杂环衍生物、其制备方法及含有该衍生物的药物组合物作为制备治疗糖尿病和代谢综合症的药物用途。所述的含氮杂环衍生物具有优异的体内降血糖活性，其可以用于预防或治疗糖尿病。
• Substituted alkylamine derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05234946A1

  公开（公告）日：1993-08-10

  The substituted alkylamine derivatives represented by formula (I) ##STR1## wherein R.sup.1 represents (a) substituted or unsubstituted C.sub.2-6 alkenyl group, (b) substituted or unsubstituted C.sub.3-6 cycloalkenyl group, (c) substituted or unsubstituted C.sub.2-6 alkynyl group, (d) substituted or unsubstituted aryl group, (e) substituted or unsubstituted heterocyclic group, (f) fused heterocyclic group which may be substituted, or (g) group represented by the formula Ru.sup.11 -Ar wherein R.sup.11 is a heterocyclic group and Ar is a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and which may be substituted; ##STR2## represents a 5- or 6-membered aromatic ring which may contain a hetero N, O or S atom, and may be substituted by R.sup.7, X and Y are linking groups, R.sup.2 is H or lower alkyl, R.sup.3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl or lower cycloalkyl, R.sup.4 and R.sup.5 are independently hydrogen or halogen atoms, R.sup.6 represents (a) substituted or unsubstituted acyclic hydrocarbon group which may be unsaturated, (b) substituted or unsubstituted cycloalkyl group, or (c) substituted or unsubstituted phenyl group, or non-toxic salts thereof. (E)-N-(6-6-dimethyl-2-hepten-4-ynyl)-N-ethyl-3-[4-(3-thienyl)-2-thienyl-me thyloxy]benzylamine hydrochloride is a representative example. The substituted alkylamine derivatives are useful as pharmaceuticals, particularly for the treatment and prevention of hypercholesterolemia, hyperlipemia and arteriosclerosis.

  公式（I）所代表的取代基烷基胺衍生物，其中R1代表（a）取代或未取代的C2-6烯丙基基团，（b）取代或未取代的C3-6环烯基基团，（c）取代或未取代的C2-6炔基基团，（d）取代或未取代的芳基基团，（e）取代或未取代的杂环基团，（f）可能被取代的融合杂环基团，或（g）由Ru11-Ar表示的基团，其中R11是杂环基团，Ar是5-或6-成员芳香环，可以含有杂原子N、O或S，且可以被取代；表示5-或6-成员芳香环，可以含有杂原子N、O或S，可以被R7取代，X和Y是连接基团，R2是H或较低的烷基，R3是氢、较低的烷基、较低的烯丙基、较低的炔基或较低的环烷基，R4和R5独立地表示氢或卤素原子，R6表示（a）取代或未取代的非环烷基，可以不饱和，（b）取代或未取代的环烷基，或（c）取代或未取代的苯基，或其非毒性盐。 （E）-N-（6-6-二甲基-2-庚烯-4-炔基）-N-乙基-3- [4-（3-噻吩基）-2-噻吩基]甲氧基]苯基胺盐酸盐是一个代表性的例子。这些取代基烷基胺衍生物可用作药物，特别是用于治疗和预防高胆固醇血症、高脂血症和动脉硬化。
• Substituted arylalkanoic acid derivatives and use thereof
  申请人：Shoda Motoshi

  公开号：US20070213333A1

  公开（公告）日：2007-09-13

  A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C 2 to C 6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.

  化合物的化学式为（I）：[在公式中，Link代表饱和或不饱和的直链碳氢链，其具有1至3个碳原子，C2至C6在芳环（E）中独立地表示构成环的碳原子，构成环的碳原子中的一个可以被V取代，V代表氮原子，或被Zx取代的碳原子，Zx代表饱和的烷基基团，其具有1至4个碳原子等，Rs代表-D-Rx等，D代表单键，氧原子等，Rx代表饱和的烷基基团，其具有3至8个碳原子等，AR代表部分不饱和或完全不饱和的紧凑双环碳环或杂环，Y代表氢原子，具有1至4个碳原子的低烷基基团等]或其盐。提供了一种具有前列腺素生成抑制作用和白三烯生成抑制作用的化合物。